Julien Klimmt

Julien Klimmt

Auto-generated profile, based on publicly available information

Julien Klimmt

Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, 81377 Munich, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Cell Reports
Verified
Journal Article
Open access
IWIsabel Weisheit
Isabel Weisheit
JKJoseph A. Kroeger
Joseph A. Kroeger
RMRainer Malik
Rainer Malik
JKJulien Klimmt
Julien Klimmt
DCDennis Crusius
Dennis Crusius
DPDominik Paquet
Dominik Paquet
CRISPR genome editing is a promising tool for translational research but can cause undesired editing outcomes, both on target at the edited locus and off target at other genomic loci. Here, we investigate the occurrence of deleterious on-target effects (OnTEs) in human stem cells after insertion of disease-related mutations by homology-directed repair (HDR) and gene editing using non-homologous end joining (NHEJ). We identify large, mono-allelic genomic deletions and loss-of-heterozygosity escaping standard quality controls in up to 40% of edited clones. To reliably detect such events, we describe simple, low-cost, and broadly applicable quantitative genotyping PCR (qgPCR) and single-nucleotide polymorphism (SNP) genotyping-based tools and suggest their usage as additional quality controls after editing. This will help to ensure the integrity of edited loci and increase the reliability of CRISPR editing.

12 January 2022 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
ARAnika Reifschneider
Anika Reifschneider
SRSophie Robinson
Sophie Robinson
BLBettina van Lengerich
Bettina van Lengerich
JGJohannes Gnörich
Johannes Gnörich
TLTodd Logan
Todd Logan
CHChristian Haass
Christian Haass
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 April 2020 in Current Opinion in Neurobiology
Verified
Journal Article
Closed access
JKJulien Klimmt
Julien Klimmt
ADAngelika Dannert
Angelika Dannert
DPDominik Paquet
Dominik Paquet

8 April 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
ADAngelika Dannert
Angelika Dannert
NSNathalie Schulz
Nathalie Schulz
JKJulien Klimmt
Julien Klimmt
LKLea Knez
Lea Knez
BGBernhard Groschup
Bernhard Groschup
DPDominik Paquet
Dominik Paquet
Tauopathies, such as Alzheimer’s disease and frontotemporal dementia, are common neurodegenerative diseases characterized by misfolding, hyperphosphorylation, and aggregation of tau. Molecular mechanisms underlying tauopathies are still poorly understood, which is in part due to a lack of human models autonomously developing major disease hallmarks. The formation of late-stage disease phenotypes may require adult tau isoform expression, which contributes to tau pathogenesis but is challenging to replicate in human stem cell–derived systems, thus impeding research on underlying mechanisms and drug development. Here, we show that induction of adult human brain–like 4R tau isoform expression enables cell-intrinsic formation of late-stage tauopathy hallmarks in induced pluripotent stem cell–derived neurons engineered to contain synergistic tau mutations without exogenous sources of tau pathology. Neurons accumulated seeding-competent and hyperphosphorylated tau in tangle-like structures. Furthermore, exclusive expression of mutant 4R in the absence of the 3R tau isoform disproportionately intensified pathology, resulting in abundant tau misfolding and aggregation. Last, we provide proof of principle that our model can be translationally applied both to test chemical disease modulators and evaluate human tau PET tracers. Collectively, our model corroborates the central role of 4R tau isoform expression for pathogenesis in human neurons and enables investigations to elucidate mechanisms underlying human tauopathy formation. Moreover, it may serve as a platform supporting urgently needed development of disease-modifying drugs.

29 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
IWIsabel Weisheit
Isabel Weisheit
JKJoseph Kroeger
Joseph Kroeger
RMRainer Malik
Rainer Malik
JKJulien Klimmt
Julien Klimmt
DCDennis Crusius
Dennis Crusius
DPDominik Paquet
Dominik Paquet
Summary: CRISPR genome editing is a promising tool for translational research but can cause undesired editing outcomes, both on-target at the edited locus and off-target at other genomic loci. We investigated the occurrence of deleterious on-target effects in human stem cells after insertion of disease-related mutations by homology-directed repair (HDR). We identified large, mono-allelic genomic deletions and loss-of-heterozygosity that escaped standard quality controls in up to 40% of edited clones. To reliably detect such events, we developed simple, low-cost and universally applicable quantitative genotyping PCR (qgPCR) as well as sequencing-based tools and suggest their usage as additional quality controls after editing. This will help to ensure the integrity of edited loci and increase the reliability of CRISPR editing.

4 August 2026 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
JKJulien Klimmt
Julien Klimmt
CGCarolina Cardoso Gonçalves
Carolina Cardoso Gonçalves
JMJessica Valentina Montgomery
Jessica Valentina Montgomery
SMStephan Alexander Mueller
Stephan Alexander Mueller
MBMerle Bublitz
Merle Bublitz
DPDominik Paquet
Dominik Paquet
Stem-cell-based in vitro models offer promising potential to elucidate human brain cell functions and interactions, but limitations in reproducibility, maturation and cell-type diversity persist. Especially, prolonged incorporation of mature microglia and studies of neuroinflammation have proven challenging. Here, we developed a human induced pluripotent stem cell-based three-dimensional cortical brain tissue model (3BTM) containing neurons, astrocytes and microglia with high reproducibility, maturity and viability. 3BTMs show morphological, functional and proteomic maturation of all cell types, leading to high similarity to their in vivo counterparts. Incorporated microglia survive for over 6 months and display mature morphology, functions and gene expression. Importantly, when engineered to model Alzheimer’s disease pathology, 3BTMs recapitulate key disease hallmarks, including amyloid deposition, increased phospho-tau levels and neuroinflammation, with microglia shifting their transcriptional landscape to disease-relevant signatures. Treatment of Alzheimer’s disease 3BTMs with anti-Aβ immunotherapy cleared deposits and largely reversed disease signatures in glia. Together, our microglia-containing model provides a platform for studying physiological and pathological states of human brain tissue.